Literature DB >> 26396111

Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.

H A Vargas1, A M Hötker2, D A Goldman3, C S Moskowitz3, T Gondo4, K Matsumoto4, B Ehdaie4, S Woo2, S W Fine5, V E Reuter5, E Sala2, H Hricak2.   

Abstract

OBJECTIVES: To evaluate the recommendations for multiparametric prostate MRI (mp-MRI) interpretation introduced in the recently updated Prostate Imaging Reporting and Data System version 2 (PI-RADSv2), and investigate the impact of pathologic tumour volume on prostate cancer (PCa) detectability on mpMRI.
METHODS: This was an institutional review board (IRB)-approved, retrospective study of 150 PCa patients who underwent mp-MRI before prostatectomy; 169 tumours ≥0.5-mL (any Gleason Score [GS]) and 37 tumours <0.5-mL (GS ≥4+3) identified on whole-mount pathology maps were located on mp-MRI consisting of T2-weighted imaging (T2WI), diffusion-weighted (DW)-MRI, and dynamic contrast-enhanced (DCE)-MRI. Corresponding PI-RADSv2 scores were assigned on each sequence and combined as recommended by PI-RADSv2. We calculated the proportion of PCa foci on whole-mount pathology correctly identified with PI-RADSv2 (dichotomized scores 1-3 vs. 4-5), stratified by pathologic tumour volume.
RESULTS: PI-RADSv2 allowed correct identification of 118/125 (94 %; 95 %CI: 90-99 %) peripheral zone (PZ) and 42/44 (95 %; 95 %CI: 89-100 %) transition zone (TZ) tumours ≥0.5 mL, but only 7/27 (26 %; 95 %CI: 10-42 %) PZ and 2/10 (20 %; 95 %CI: 0-52 %) TZ tumours with a GS ≥4+3, but <0.5 mL. DCE-MRI aided detection of 4/125 PZ tumours ≥0.5 mL and 0/27 PZ tumours <0.5 mL.
CONCLUSIONS: PI-RADSv2 correctly identified 94-95 % of PCa foci ≥0.5 mL, but was limited for the assessment of GS ≥4+3 tumours ≤0.5 mL. DCE-MRI offered limited added value to T2WI+DW-MRI. KEY POINTS: • PI-RADSv2 correctly identified 95 % of PCa foci ≥0.5 mL • PI-RADSv2 was limited for the assessment of GS ≥4+3 tumours ≤0.5 mL • DCE-MRI offered limited added value to T2WI+DW-MRI.

Entities:  

Keywords:  DCE; Diffusion; MRI; PI-RADS; Prostate cancer

Mesh:

Year:  2015        PMID: 26396111      PMCID: PMC4803633          DOI: 10.1007/s00330-015-4015-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  10 in total

1.  Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores.

Authors:  Andreas Wibmer; Hedvig Hricak; Tatsuo Gondo; Kazuhiro Matsumoto; Harini Veeraraghavan; Duc Fehr; Junting Zheng; Debra Goldman; Chaya Moskowitz; Samson W Fine; Victor E Reuter; James Eastham; Evis Sala; Hebert Alberto Vargas
Journal:  Eur Radiol       Date:  2015-05-21       Impact factor: 5.315

2.  Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study.

Authors:  Hebert Alberto Vargas; Oguz Akin; Amita Shukla-Dave; Jingbo Zhang; Kristen L Zakian; Junting Zheng; Kent Kanao; Debra A Goldman; Chaya S Moskowitz; Victor E Reuter; James A Eastham; Peter T Scardino; Hedvig Hricak
Journal:  Radiology       Date:  2012-09-05       Impact factor: 11.105

Review 3.  Overdiagnosis and overtreatment of prostate cancer.

Authors:  Stacy Loeb; Marc A Bjurlin; Joseph Nicholson; Teuvo L Tammela; David F Penson; H Ballentine Carter; Peter Carroll; Ruth Etzioni
Journal:  Eur Urol       Date:  2014-01-09       Impact factor: 20.096

4.  Modernizing the diagnostic and decision-making pathway for prostate cancer.

Authors:  Thomas J Polascik; Niccolo' M Passoni; Arnauld Villers; Peter L Choyke
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

Review 5.  The contemporary concept of significant versus insignificant prostate cancer.

Authors:  Guillaume Ploussard; Jonathan I Epstein; Rodolfo Montironi; Peter R Carroll; Manfred Wirth; Marc-Oliver Grimm; Anders S Bjartell; Francesco Montorsi; Stephen J Freedland; Andreas Erbersdobler; Theodorus H van der Kwast
Journal:  Eur Urol       Date:  2011-05-17       Impact factor: 20.096

6.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

Review 7.  Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis.

Authors:  Esther H J Hamoen; Maarten de Rooij; J Alfred Witjes; Jelle O Barentsz; Maroeska M Rovers
Journal:  Eur Urol       Date:  2014-11-06       Impact factor: 20.096

8.  Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy.

Authors:  Tiphaine Vaché; Flavie Bratan; Florence Mège-Lechevallier; Sylvain Roche; Muriel Rabilloud; Olivier Rouvière
Journal:  Radiology       Date:  2014-06-15       Impact factor: 11.105

9.  Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales.

Authors:  Andrew B Rosenkrantz; Sooah Kim; Ruth P Lim; Nicole Hindman; Fang-Ming Deng; James S Babb; Samir S Taneja
Journal:  Radiology       Date:  2013-06-20       Impact factor: 11.105

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

  10 in total
  101 in total

1.  Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study.

Authors:  Matthew D Greer; Anna M Brown; Joanna H Shih; Ronald M Summers; Jamie Marko; Yan Mee Law; Sandeep Sankineni; Arvin K George; Maria J Merino; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  J Magn Reson Imaging       Date:  2016-07-08       Impact factor: 4.813

2.  A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).

Authors:  Sonia Gaur; Stephanie Harmon; Rajan T Gupta; Daniel J Margolis; Nathan Lay; Sherif Mehralivand; Maria J Merino; Bradford J Wood; Peter A Pinto; Joanna H Shih; Peter L Choyke; Baris Turkbey
Journal:  Acad Radiol       Date:  2018-04-25       Impact factor: 3.173

3.  Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.

Authors:  Mrishta Brizmohun Appayya; Harbir S Sidhu; Nikolaos Dikaios; Edward W Johnston; Lucy Am Simmons; Alex Freeman; Alexander Ps Kirkham; Hashim U Ahmed; Shonit Punwani
Journal:  Br J Radiol       Date:  2017-12-15       Impact factor: 3.039

4.  AI-based applications in hybrid imaging: how to build smart and truly multi-parametric decision models for radiomics.

Authors:  Isabella Castiglioni; Francesca Gallivanone; Paolo Soda; Michele Avanzo; Joseph Stancanello; Marco Aiello; Matteo Interlenghi; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-11       Impact factor: 9.236

5.  [Value of PI-RADS v2 scores combined with prostate specific antigen in diagnosis of peripheral zone prostate cancer: a logistic regression analysis].

Authors:  Li-Zhi Lei; Yi-Kai Xu; Mei-Rong Hou; Meng-Qi He
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-08-20

Review 6.  Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.

Authors:  Jonathan H Wang; Tracy M Downs; E Jason Abel; Kyle A Richards; David F Jarrard
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

7.  Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.

Authors:  Takeshi Hashimoto; Krishnan Rahul; Toshikazu Takeda; Nicole Benfante; John P Mulhall; Hedvig Hricak; James A Eastham; Hebert Alberto Vargas
Journal:  Urol Oncol       Date:  2016-09-22       Impact factor: 3.498

Review 8.  Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI.

Authors:  Ryan L Brunsing; Natalie M Schenker-Ahmed; Nathan S White; J Kellogg Parsons; Christopher Kane; Joshua Kuperman; Hauke Bartsch; Andrew Karim Kader; Rebecca Rakow-Penner; Tyler M Seibert; Daniel Margolis; Steven S Raman; Carrie R McDonald; Nikdokht Farid; Santosh Kesari; Donna Hansel; Ahmed Shabaik; Anders M Dale; David S Karow
Journal:  J Magn Reson Imaging       Date:  2016-08-16       Impact factor: 4.813

9.  Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Authors:  Anwar R Padhani; Jeffrey Weinreb; Andrew B Rosenkrantz; Geert Villeirs; Baris Turkbey; Jelle Barentsz
Journal:  Eur Urol       Date:  2018-06-13       Impact factor: 20.096

Review 10.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.